GW Pharmaceuticals Announces the Closing of Public Offering of ADSs
Gabrielle Lakusta - October 5th, 2018
GW Pharmaceuticals (Nasdaq:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 1,900,000 American Depositary Shares and the full exercise by the underwriters of their option to purchase … Continued
GW Pharmaceuticals (Nasdaq:GWPH), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced today the closing of the previously announced underwritten public offering on the Nasdaq Global Market by GW of 1,900,000 American Depositary Shares and the full exercise by the underwriters of their option to purchase 285,000 additional ADSs from GW at a price to the public of $158.00 per ADS, raising gross proceeds of $345,230,000 (before deducting underwriting discounts, commissions and offering expenses).
As quoted in the press release:
The ADSs described above were offered by GW pursuant to a shelf registration statement filed by GW with the Securities and Exchange Commission ("SEC") that became automatically effective on April 17, 2017. A prospectus supplement related to the offering has been filed with the SEC and is available on the SEC's website at http://www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to this offering may be obtained from Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 1-866-471-2526, facsimile: 212-902-9316 or by emailing prospectusgroup-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014; J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 592-5973 or by emailing PostSaleManualRequests@broadridge.com.
Click here to read the full press release.
We found the top performing pharma stocks to watch this year
Find out more in our report
Leveraging Cannabinoids in Pediatric Medicine
Cannabis ETFs — Should You Invest?
Marijuana Stocks by Industry
The Future of Medical Cannabis: Cannabinoid-based Pharmaceuticals
Tags: american depositary shares, GW Pharmaceuticals, NASDAQ:GWPH
Harvest One